SEC Tracker
Get the app

Surrozen SRZN

Surrozen FY 2022: net loss $36.0M; diluted EPS −$1.04

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Surrozen reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$36.0MAgainst −$54.6M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS−$1.04Against −$2.21 in FY 202110-K income statement, on EDGAR
  3. Cash and cash equivalents$24.7M−25% from $33.1M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$44.1MAgainst −$48.8M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Surrozen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  2. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  3. iBio IBIO public float $58M, Dec 31, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Lifevantage LFVN public float $64M, Dec 31, 2025